Drugs that contain Abacavir Sulfate; Dolutegravir Sodium; Lamivudine
1. Drug name - TRIUMEQ
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8129385 | VIIV HLTHCARE | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
Oct, 2027
(5 years from now) | |
| US9242986 | VIIV HLTHCARE | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
Dec, 2029
(7 years from now) | |
| CN101346376A | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase |
Jul, 2011
(11 years ago) | |
| CN101212903A | VIIV HLTHCARE | Polycyclic Carbamoyl Pyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
| CN101212903B | VIIV HLTHCARE | Polycyclic Carbamoyl Pyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
| CN102245182A | VIIV HLTHCARE | Synthesis Of Carbamoyl Pyridone Hiv Integrase Inhibitors And Intermediate |
Dec, 2029
(7 years from now) | |
| CN102245182B | VIIV HLTHCARE | Carbamoyl Pyridone Hiv Integrase Inhibitors And Intermediates For Synthesis |
Dec, 2029
(7 years from now) | |
| IN373756B | VIIV HLTHCARE | Process For The Preparation Of Carbamoylpyrid One Hiv Integrase Inhibitors |
Dec, 2029
(7 years from now) | |
| IN201838011858A | VIIV HLTHCARE | Process For The Preparation Of Carbamoylpyridone Hiv Integrase Inhibitors |
Dec, 2029
(7 years from now) | |
| EP1852434A1 | VIIV HLTHCARE | Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibiting Activity |
Feb, 2026
(3 years from now) | |
| EP1852434B1 | VIIV HLTHCARE | Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibiting Activity |
Feb, 2026
(3 years from now) | |
| EP1852434A4 | VIIV HLTHCARE | Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibiting Activity |
Feb, 2026
(3 years from now) | |
| EP2527007B1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
| EP3372281A1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
| EP3187225B1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
| EP3045206A1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
| EP3284520A1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
| EP3284520B1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
| EP3187225A1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
| EP3372281B1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
| EP3045206B1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
| EP2527007A1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
| EP1874117B8 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
| EP1874117A4 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
| EP2465580A1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivatives Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
| EP1874117A1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
| EP1874117B1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
| EP2465580B1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivatives Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
| EP1950212B1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase |
Oct, 2026
(4 years from now) | |
| EP1950212A4 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase |
Oct, 2026
(4 years from now) | |
| EP1950212A1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase |
Oct, 2026
(4 years from now) | |
| EP2376080A1 | VIIV HLTHCARE | Synthesis Of Carbamoylpyridone Hiv Integrase Inhibitors And Intermediates |
Dec, 2029
(7 years from now) | |
| EP2376080B1 | VIIV HLTHCARE | Synthesis Of Carbamoylpyridone Hiv Integrase Inhibitors And Intermediates |
Dec, 2029
(7 years from now) | |
| EP2376080A4 | VIIV HLTHCARE | Synthesis Of Carbamoylpyridone Hiv Integrase Inhibitors And Intermediates |
Dec, 2029
(7 years from now) | |
Treatment: NA
Dosage: TABLET;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| EQ 600MG BASE;EQ 50MG BASE;300MG | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.